Back to mobile site
Get it on Google Play

FDA extends review of Lantheus' LNTH-2501 imaging drug by three months

March 17, 2026 4:01 PM EDT Send to a Friend
Lantheus Holdings Inc. (NASDAQ: LNTH) announced the U.S. Food and Drug Administration has extended its review of the New Drug ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login